KRAS and lung carcinoma: Moreover, cells with the presence of the WT KRAS allele together with mutant KRAS were sensitive towards the FoxM1 inhibitor siomycin, suggesting that the targeting of FoxM1 could be a therapeutic approach in the treatment of lung cancer with both the WT and mutant KRAS alleles [26].